Company Name Change
Change of company name from Admedus to Anteris Technologies
Creating the World's Most Durable Heart Valve
Admedus AGM 2020
Admedus 2020 AGM CEO Presentation
Admedus 2020 AGM
Admedus 2020 AGM Video
CEO Wayne Paterson is interviewed by Proactive Investors
CEO Wayne Paterson is interviewed by proactive investors to provide an update on Admedus in light of COVID-19
First patient implanted with DurAVR™
Admedus implants first patient with their 3D single piece aortic valve
Admedus is proud to announce the successful implantation of its ADAPT® treated single piece 3D aortic valve.
Admedus Limited announces the first implantation of its ADAPT® treated 3D single piece aortic valve in a patient with aortic stenosis.
Investor Q&A with Dr. Paul Sorajja & our CEO
Dr. Paul Sorajja shares his view on Admedus' TAVR
Credit Suisse Equity Research – US Medical Supplies & Devices
Week of Pre-Releases and Meetings Point to Solid Fundamentals and Healthy Innovation See the report here
First-In-Human SAVR Trial Begins Q1 2020
ANNOUNCEMENT First-In-Human SAVR Trial Begins Q1 2020. Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals.
CEO Wayne Paterson discusses the opportunities in the TAVR market
Since taking the helm of Admedus Ltd. in 2017, CEO, Wayne Paterson has steered the ASX small-cap company into a real contender for disrupting the global transcatheter aortic valve replacement (TAVR) market. Its innovative ADAPT® technology not only slashes surgical…
ADAPT tissue is “going to be a game-changer”
Michael Reardon (Houston, USA) talks to BLearning Cardio about the ADAPT tissue technology (Admedus), and the increasing importance of durability as TAVI moves to younger and lower risk patients. Reardon notes that “we would like to have technology that does…